Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Aug 14, 2014; 20(30): 10405-10418
Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10405
Table 2 Core data, characterizing outcome of neoadjuvant chemoradiation and surgery, vs upfront surgery plus adjuvant chemotherapy in patients with resectable and/or borderline resectable pancreatic tumor
Ref.Patients includedInclusion periodeTreatment algorithmProportion not resectedR0 statusFrequency of vascular resectionMedian survival in months
Katz et al[63] 20081601999-2006Neo-adjuvant59%94%27%40
Nordby et al[84] 20131352008-2010Upfront surgery+ adjuvance11%42%6%Na1
Neop-tolemos et al[76] 201010882000-2007Upfront surgery+ adjuvanceOnly resected patients included65%17%23
Schmidt et al[77] 20121322004-2007Upfront surgery+ adjuvanceOnly resected patients included61%Na228